
Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to this upfront sum, Paris-headquartered Sanofi …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

